Last reviewed · How we verify

NCT04671407

The Aim of This Study is to Compare the Efficacy of Perioperative Hypertonic Saline 3% Versus Normal Saline (0.9%) in Decreasing Recurrence Risk in Non-muscle Invasive Bladder Cancer

Status unknown Phase 2 Last updated 18 February 2021
What this trial tests

Phase 2 trial testing Hypertonic Saline in TCC in 150 participants. Status unknown.

Timeline
20 January 2021
Primary endpoint
1 December 2022
1 December 2022

Quick facts

Lead sponsorKaplan Medical Center
PhasePhase 2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeprevention
Enrollment150
Start date20 January 2021
Primary completion1 December 2022
Estimated completion1 December 2022
Sites1 location across Israel

Drugs / interventions tested

Conditions studied

Sponsor

Kaplan Medical Center

Who can join

Adults 18 to 99, any sex, with TCC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Purpose: to demonstrate a 10% recurrence risk reduction for patients treated with Hypersal versus normal saline immediately following TURBT. Design: prospective randomized double-blind placebo controlled trial. Outline: eligible patients with non-muscle invasive bladder cancer who undergo TURBT at our center will be randomized to receive either 40ml of normal saline or 40 ml of hypersal intravesically. The primary endpoint is tumor recurrence rate. Secondary endpoint are time to recurrence and side effects. Patients A total of 150 patients will be enrolled in this trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Hypertonic Saline

Trials testing the same drug.

Other Kaplan Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04671407.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing